View Exam | PowerPak

1. A diagnosis of breakthrough pain requires _______________.

A. Controlled persistent baseline pain B. More than 3 episodes of intense pain daily C. An underlying cancer diagnosis D. Pain that is moderate or severe for most of the day

2. A patient on oxycodone extended-release for chemotherapy-induced neuropathic pain who reports consistent increases in her pain level 1 hour before her scheduled opioid dose in the morning or evening is likely experiencing ________.

A. Predictable incident breakthrough pain B. Unpredictable incident breakthrough pain C. Idiopathic breakthrough pain D. End-of-dose failure

3. A patient with cancer pain that is treated with oxycodone extended-release 20 mg twice daily experiences debilitating increases in pain each time she walks her dog. The preferred pharmacologic approach is to _____________.

A. Double her daily dose of oxycodone extended-release B. Rotate to morphine extended-release 20 mg twice daily C. Provide a short-acting rescue medication to be taken before the precipitating activity D. Provide a short-acting rescue medication to be taken after the precipitating activity

4. Transmucosal immediate-release fentanyl medications should only be prescribed to patients who are ___________.

A. Treated in an inpatient setting B. Experiencing inflammatory breakthrough pain C. Not taking any other opioids D. Opioid tolerant

5. A patient must be taking at least _________ oxycodone 5 mg tablets each day for more than 1 week to meet the definition of opioid-tolerant from the US Food and Drug Administration.

A. 1 B. 2 C. 4 D. 6

6. Fentanyl is used in prescription opioid formulations designed to treat cancer-related breakthrough pain because it is ________.

A. Not associated with risks of constipation B. Inherently long-acting C. Lipophilic D. Less abusable than other opioids

7. The appropriate initial dose of a transmucosal immediate-release fentanyl medication for a patient with cancer-related breakthrough pain is _________.

A. The lowest available dose B. 15% of the daily opioid dose C. 25% of the daily opioid dose D. 35% of the daily opioid dose

8. The Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl medications includes ___________.

A. A medication guide for all outpatients B. A program registration requirement for physicians prescribing to outpatients C. A program registration requirement for dispensing pharmacists D. All of the above

9. How often do you NOW PLAN TO stratify your patients with chronic pain for risks of aberrant drug-taking behavior before prescribing long-term opioid therapy?

A. Never B. About 25% of the time C. About 50% of the time D. About 75% of the time E. About 100% of the time

10. How often do you NOW PLAN TO tailor therapy for breakthrough pain based on the temporal profile and predictability of the episodes?

A. Never B. About 25% of the time C. About 50% of the time D. About 75% of the time E. About 100% of the time

Maintenance is scheduled for 05/15/2024 5:00 PM EST - 05/16/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. A diagnosis of breakthrough pain requires _______________.

2. A patient on oxycodone extended-release for chemotherapy-induced neuropathic pain who reports consistent increases in her pain level 1 hour before her scheduled opioid dose in the morning or evening is likely experiencing ________.

3. A patient with cancer pain that is treated with oxycodone extended-release 20 mg twice daily experiences debilitating increases in pain each time she walks her dog. The preferred pharmacologic approach is to _____________.

4. Transmucosal immediate-release fentanyl medications should only be prescribed to patients who are ___________.

5. A patient must be taking at least _________ oxycodone 5 mg tablets each day for more than 1 week to meet the definition of opioid-tolerant from the US Food and Drug Administration.

6. Fentanyl is used in prescription opioid formulations designed to treat cancer-related breakthrough pain because it is ________.

7. The appropriate initial dose of a transmucosal immediate-release fentanyl medication for a patient with cancer-related breakthrough pain is _________.

8. The Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl medications includes ___________.

9. How often do you NOW PLAN TO stratify your patients with chronic pain for risks of aberrant drug-taking behavior before prescribing long-term opioid therapy?

10. How often do you NOW PLAN TO tailor therapy for breakthrough pain based on the temporal profile and predictability of the episodes?

« Return to Activity

Maintenance is scheduled for 05/15/2024 5:00 PM EST - 05/16/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. A diagnosis of breakthrough pain requires _______________.

2. A patient on oxycodone extended-release for chemotherapy-induced neuropathic pain who reports consistent increases in her pain level 1 hour before her scheduled opioid dose in the morning or evening is likely experiencing ________.

3. A patient with cancer pain that is treated with oxycodone extended-release 20 mg twice daily experiences debilitating increases in pain each time she walks her dog. The preferred pharmacologic approach is to _____________.

4. Transmucosal immediate-release fentanyl medications should only be prescribed to patients who are ___________.

5. A patient must be taking at least _________ oxycodone 5 mg tablets each day for more than 1 week to meet the definition of opioid-tolerant from the US Food and Drug Administration.

6. Fentanyl is used in prescription opioid formulations designed to treat cancer-related breakthrough pain because it is ________.

7. The appropriate initial dose of a transmucosal immediate-release fentanyl medication for a patient with cancer-related breakthrough pain is _________.

8. The Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl medications includes ___________.

9. How often do you NOW PLAN TO stratify your patients with chronic pain for risks of aberrant drug-taking behavior before prescribing long-term opioid therapy?

10. How often do you NOW PLAN TO tailor therapy for breakthrough pain based on the temporal profile and predictability of the episodes?

« Return to Activity

Customers who Purchased
this Activity also Purchased